Loading…
Artiva Biotherapeutics, Inc. is projected to rise to $13.31 by 2027, a +38% move from its current price of $9.64. ARTV is currently trading above its 50-day average (a bullish sign). Technical indicators currently lean strong buy.
A data-driven summary — not financial advice. See the full breakdown below.
Live market data via Yahoo Finance · updated 7/12/2026
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| Jul 13 | $9.24 | $9.65 | $10.07 | +0.08% |
| Jul 14 | $9.08 | $9.66 | $10.26 | +0.16% |
| Jul 15 | $8.97 | $9.66 | $10.41 | +0.24% |
| Jul 16 | $8.87 | $9.67 | $10.54 | +0.32% |
| Jul 17 | $8.79 | $9.68 | $10.66 | +0.40% |
| Jul 18 | $8.71 | $9.69 | $10.77 | +0.48% |
| Jul 19 | $8.65 | $9.69 | $10.87 | +0.56% |
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| Week 1 | $8.65 | $9.69 | $10.87 | +0.56% |
| Week 2 | $8.29 | $9.75 | $11.46 | +1.13% |
| Week 3 | $8.04 | $9.80 | $11.95 | +1.70% |
| Week 4 | $7.84 | $9.86 | $12.39 | +2.27% |
| Week 5 | $7.68 | $9.91 | $12.80 | +2.84% |
| Week 6 | $7.54 | $9.97 | $13.19 | +3.42% |
| Week 7 | $7.41 | $10.03 | $13.57 | +4.00% |
Short-term targets derived from the forecast trend and recent volatility. Highly uncertain — not financial advice.
Artiva Biotherapeutics, Inc. is a clinical-stage biotechnology company focused on developing natural killer (NK) cell–based therapies for patients suffering from autoimmune diseases and cancers. Its lead product candidate includes AlloNK, an off-the-shelf NK cell therapy for patients with autoimmune diseases and cancers, such as rheumatoid arthritis, systemic lupus erythematosus, lupus nephritis, rheumatoid arthritis, pemphigus vulgaris, the anti-neutrophil cytoplasmic antibody -associated vasculitis subtypes granulomatosis with polyangiitis/microscopic polyangiitis, and B-cell-non-Hodgkin lymphoma.
The company also develops AB-201, an allogeneic anti-human epidermal growth factor receptor 2 targeting chimeric antigen receptor (CAR)-NK cell product candidate for the treatment of various solid tumors, such as breast, gastric and esophageal, and bladder cancers; and AB-205, an allogeneic anti-CD5 CAR-NK cell product candidate for the treatment of hematological malignancies. Artiva Biotherapeutics, Inc. was incorporated in 2019 and is headquartered in San Diego, California.
Artiva Biotherapeutics, Inc. (ARTV) is a biotechnology company focused on healthcare solutions in the NK cell therapy space. The current price is $9.62 and the market capitalization is $467.42M, with a market rank of 3102.
The stock’s technical snapshot shows bullish sentiment, RSI(14) at 50, SMA50 at $9.48, SMA200 at $5.61, a support level at $6.80 and a resistance level at $10.68, and a 30-day price range of $6.71 to $13.80. The annualized volatility is 100%.
A major floor 48.0% below — a decisive break under it would weaken the trend.
The nearest floor, 29.5% below — buyers have tended to step in here.
The nearest ceiling, 3.1% above — a clean break opens room to run.
A major ceiling 38.9% above — clearing it would confirm fresh momentum.
Key ARTV support and resistance from recent price action — levels where the trend has historically paused or reversed. Percentages are the distance from the current price.
A snapshot of ARTV market posture derived from its technical indicators and recent volatility. Higher trend and alignment lean bullish; higher risk means larger swings.
Technical Analysis
Indicators computed on daily closing prices.
| Period | SMA | Action | EMA | Action |
|---|---|---|---|---|
| MA 5 | $9.46 | Buy | $9.51 | Buy |
| MA 10 | $9.56 | Buy | $9.46 | Buy |
| MA 20 | $9.36 | Buy | $9.26 | Buy |
| MA 50 | $9.13 | Buy | $8.86 | Buy |
| MA 100 | $8.02 | Buy | $8.00 | Buy |
| MA 200 | $5.96 | Buy | $6.82 | Buy |
| Name | Value | Action |
|---|---|---|
| RSI (14) | 55.84 | Neutral |
| Stoch RSI (14) | 59.67 | Neutral |
| CCI (20) | 52.99 | Neutral |
| Williams %R (14) | -16.49 | Info |
| MACD (12,26,9) | 0.00 | Buy |
| ROC (12) | -1.63 | Sell |
| Bollinger %B (20,2) | 0.65 | Neutral |
| Stochastic %K (14) | 83.51 | Sell |
| TRIX (15) | 0.41 | Buy |
| Awesome (5,34) | 0.89 | Buy |
| Ultimate (7,14,28) | 48.79 | Neutral |
| Momentum (10) | 0.81 | Buy |
| Aroon Osc (25) | 28.00 | Buy |
| Hull MA (9) | 9.39 | Buy |
| ADX (14) | 12.92 | Neutral |
| ATR (14) | 0.32 | Info |
The 30-day technical picture shows a BULLISH sentiment with an RSI of 50. The stock trades with a SMA50 of $9.48 and a SMA200 of $5.61, indicating near-term momentum around the mid-$9s. The 30-day range runs from $6.71 to $13.80, with a defined support at $6.80 and resistance at $10.68.
These levels suggest there could be upside potential from current levels, though volatility remains a factor.
| Year | Min | Avg | Max | ROI | Sentiment |
|---|---|---|---|---|---|
| $3.74 | $9.64 | $14.65 | 0% | Neutral | |
| $10.02 | $13.31 | $19.00 | +38% | Bullish | |
| $14.25 | $19.83 | $29.86 | +106% | Bullish | |
| $15.15 | $21.94 | $34.45 | +128% | Bullish | |
| $14.17 | $21.27 | $34.58 | +121% | Bullish | |
| $16.34 | $25.34 | $42.44 | +163% | Bullish | |
| $15.94 | $25.50 | $43.87 | +165% | Bullish | |
| $15.87 | $26.16 | $46.09 | +171% | Bullish | |
| $20.21 | $34.28 | $61.73 | +256% | Bullish | |
| $23.95 | $41.76 | $76.73 | +333% | Bullish | |
| $26.57 | $52.76 | $105.38 | +447% | Bullish | |
| $62.41 | $138.68 | $311.88 | +13.4x | Bullish |
Current year — the forecast is anchored to the live price, so ROI shows 0%.
| Month | Min | Avg | Max | Change |
|---|---|---|---|---|
| July 2026 | $3.74 | $9.64 | $12.22 | +0.00% |
| August 2026 | $8.90 | $10.67 | $13.25 | +10.63% |
| September 2026 | $8.55 | $10.37 | $13.10 | -2.76% |
| October 2026 | $8.36 | $10.24 | $13.12 | -1.28% |
| November 2026 | $8.82 | $10.88 | $14.12 | +6.31% |
| December 2026 | $8.98 | $11.17 | $14.65 | +2.65% |
Click any year to see its month-by-month ARTV forecast. Min / Avg / Max are a bear / base / bull scenario; ROI is the projected move from the current price. Change is the month-over-month move in the average. Estimates, not guarantees.
In 2026, ARTV is projected to trade between $3.74 and $14.65, averaging $9.64 — a potential gain of 0% from today's $9.64. Price action looks broadly range-bound.
Artiva Biotherapeutics, Inc.'s 2027 outlook centres on $13.31, within a $10.02 to $19.00 range. That is up +38% on the projected 2026 average. That marks a +38% change versus current levels. Buyers look set to stay in control over this stretch.
By 2028, ARTV could reach as high as $29.86, with a base case around $19.83 and support toward $14.25 — roughly +106% from $9.64. Momentum favours further upside here.
Expect ARTV to range from $15.15 to $34.45 through 2029. The $21.94 average target implies a +128% move from current prices. That is up +11% on the projected 2028 average. Buyers look set to stay in control over this stretch.
The ARTV price prediction for 2030 points to an average of $21.27 (low $14.17, high $34.58) — a potential gain of +121% on today's $9.64. Momentum favours further upside here.
In 2031, ARTV is projected to trade between $16.34 and $42.44, averaging $25.34 — a potential gain of +163% from today's $9.64. That is up +19% on the projected 2030 average. Buyers look set to stay in control over this stretch.
Artiva Biotherapeutics, Inc.'s 2032 outlook centres on $25.50, within a $15.94 to $43.87 range. That is up +1% on the projected 2031 average. That marks a +165% change versus current levels. Momentum favours further upside here.
By 2033, ARTV could reach as high as $46.09, with a base case around $26.16 and support toward $15.87 — roughly +171% from $9.64. Buyers look set to stay in control over this stretch.
Expect ARTV to range from $20.21 to $61.73 through 2034. The $34.28 average target implies a +256% move from current prices. That is up +31% on the projected 2033 average. Momentum favours further upside here.
The ARTV price prediction for 2035 points to an average of $41.76 (low $23.95, high $76.73) — a potential gain of +333% on today's $9.64. Buyers look set to stay in control over this stretch.
In 2040, ARTV is projected to trade between $26.57 and $105.38, averaging $52.76 — a potential gain of +447% from today's $9.64. That is up +26% on the projected 2035 average. Momentum favours further upside here.
Artiva Biotherapeutics, Inc.'s 2050 outlook centres on $138.68, within a $62.41 to $311.88 range. That is up +163% on the projected 2040 average. That marks a +13.4x change versus current levels. Buyers look set to stay in control over this stretch.
Investing $1,000 in ARTV today (≈ 103.73444 ARTV) could be worth
$14,385.72
+$13,385.72 (+1339%) by 2050 · US Dollar
Based on the average projected ARTV price of $138.68 in 2050.
Based on the base (average) forecast scenario. FX rates are indicative. Estimates only — not financial advice.
See what a past investment in ARTVwould be worth at today's price.
$1,000 invested in ARTV on Jul 10, 2025 (≈ 558.65923 ARTV) would be worth
$5,385.47
+$4,385.47 (+438.5%) today · 5.39× · US Dollar
Based on a ARTV entry price of $1.79 vs. today's $9.64.
| Invested | Entry price | Value today | Return |
|---|---|---|---|
| 1 week ago | $9.61 | $1,003.12 | +0.3% |
| 1 month ago | $7.42 | $1,299.19 | +29.9% |
| 3 months ago | $6.81 | $1,415.57 | +41.6% |
| 6 months ago | $4.88 | $1,975.41 | +97.5% |
| 1 year ago | $1.79 | $5,385.47 | +438.5% |
| All time (2.0y) ago | $12 | $803.33 | -19.7% |
Past performance from historical market data — it does not predict future results. FX rates are indicative. Not financial advice.
Enter a price to see how it sits against our ARTV forecast.
Our base-case forecast reaches $19.00 around 2028.
Implied market cap at $19.00: $923.18M
The multi-year forecast provides a path of rising averages and upside potential, with the 2026 avg at $9.62 (ROI 0, NEUTRAL). The 2027 avg is $15.93 (ROI 65.6, BULLISH), the 2028 avg is $25.12 (ROI 161.1, BULLISH), and the 2029 avg is $26.86 (ROI 179.2, BULLISH). For 2030, the avg is $26.43 (ROI 174.8, BULLISH).
From 2031 to 2035 the forecast shows continued upside growth, with 2031 avg $33.82 (ROI 251.5) and 2032 avg $32.10 (ROI 233.7), 2033 avg $34.67 (ROI 260.4), 2034 avg $52.30 (ROI 443.6), and 2035 avg $61.68 (ROI 541.2); all are BULLISH. In 2040, the avg is $82.66 (ROI 759.3) and in 2050 the avg is $231.14 (ROI 2302.7), both with a BULLISH sentiment. These figures are estimates and not guarantees, and they illustrate a potential trajectory rather than a guaranteed outcome.
Tap a question to reveal the answer.
The 2030 forecast shows min $16.31, avg $26.43, max $45.94; ROI 174.8; sentiment BULLISH.
The forecast presents a path with years of BULLISH sentiment and ROIs ranging from 65.6 to 541.2, and notable upside by 2040 and 2050, but these are estimates and not guaranteed.
The projections include a max of $102.19 in 2034 and $181.57 in 2040, indicating a potential to exceed $100 according to the forecasts, though not guaranteed.
Current price is $9.62 and market capitalization is $467.42M.
The 2050 forecast shows min $104.01, avg $231.14, max $531.63; ROI 2302.7; sentiment BULLISH.
Artiva Biotherapeutics, Inc. Community Discussion
0Share your Artiva Biotherapeutics, Inc. price prediction and read what the community thinks. Be respectful — comments are public and not financial advice.
Be the first to share your prediction…
What's your take? Add a comment above to start the conversation.